Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=85 S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer
Lung Cancer
Primary: Feasibility of Pharmacogenomics-based Treatment Assignment in the Cooperative Group Setting — 71 Participants
N/A N=35 Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer
Lung Cancer
Primary: Boost Dose Toxicity — 5 Participants
Phase 2 N=71 Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…
Phase 2 N=105 Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Phase 2 N=75 Preoperative Therapy in Patients With Stages IB, II, IIIA, and Selected IIIB Patients With Non-Small Cell Lung Cancer
Lung Cancer
Primary: Pathologic Complete Response Rate — 0 Percentage of participants
Phase 2 N=82 Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 29; 50 percentage of participants
Phase 3 N=1,047 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery
Lung Cancer
Primary: Overall Survival in Lymph Nodes Examined Patients — NA; NA years — p=0.007
Phase 2 N=75 Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC
Lung Cancer
Primary: Number of Participants Who Completed Four Cycles of the Carboplatin/Docetaxel Regimen — 57 Participants
Phase 2 N=59 Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
Lung Cancer
Primary: Local Control at 2 Years — 97.6 percentage of subjects — p=0.013
Phase 2 N=35 Phase II Iressa & Carbo/Gem in NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Progression Free Survival (PFS) — 131.0; 42.0 Days
Phase 2 N=117 Navelbine And Radiotherapy in Locally Advanced Lung Cancer
Non-small Cell Lung Cancer
Primary: Local Failure Free Survival — 9.4; 9.9 months
Phase 2 N=24 Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
Primary: Percentage of Subjects With Detectable Circulating T Cells After Treatment — 16.7 Percentage of participants
Phase 2 N=128 Icotinib for Completed Resected IB NSCLC With EGFR Mutation
Lung Neoplasms · Squamous Cell Lung Cancer · Adenocarcinoma of the Lung
Primary: 3-year Disease-Free Survival — 96.1; 84.0 Percentage of patients at 3 years
Phase 2 N=112 Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
Non-Small Cell Lung Cancer
Primary: Disease-free Survival — NA; 55.1 months
Phase 3 N=598 Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
N/A N=29 Stereotactic Body Radiation Therapy (SBRT) in Metastatic Non-small Cell Lung Cancer
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Phase 2 N=48 Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer
Lung Cancer · Non-small Cell Lung Cancer (NSCLC)
Primary: Progression-free Survival (PFS) — 8.7 months
Phase 2 N=84 S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
Lung Cancer
Primary: Overall Survival — 21 months
Phase 2 N=15 Tarceva And Radiotherapy in Locally Advanced Lung Cancer Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Primary: Progression Free Survival — 9.4 months
Phase 3 N=503 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
Adenocarcinoma of the Lung · Adenosquamous Cell Lung Cancer · Bronchoalveolar Cell Lung Cancer
Primary: Overall Survival — 0.52; 0.57 percentage of 5 years survival rate — p=0.14
Phase 2 N=46 Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
Non Small Cell Lung Cancer
Primary: Progression Free Survival — 77.1 percentage of participants
Phase 2 N=64 Atezolizumab Immunotherapy in Patients With Advanced NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control Rate (DCR) After 12 Weeks Induction — 0.742 proportion of participants
Phase 2 N=59 S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Lung Cancer
Primary: Selection of One of Two Treatment Regimens (Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel) for Further Study in a Phase III Trial, Based on Median…
Phase 2 N=33 Stereotactic Body Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer That Can Be Removed By Surgery
Lung Cancer
Primary: Primary Tumor Control at 2 Years — 96.2 percentage of patients
Phase 3 N=222 Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
Lung Cancer
Primary: Time to Local Recurrence — NA; NA years — p=0.98
Phase 2 N=49 Surgery and/or Radiation Therapy or Standard Therapy and/or Clinical Observation in Treating Patients With Previously Treated Stage IV Non-small Cell Lung Cancer
Recurrent Lung Non-Small Cell Carcinoma · Stage IV Non-Small Cell Lung Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 14.2; 4.4 Months
Phase 2 N=98 Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
Lung Cancer
Primary: Incidence of AE Grade 3 or Higher Toxicity — 24; 26 Participants
Phase 2 N=35 Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer · Lung Cancer, Non-Small Cell
Primary: Number of Participants Achieving Tumor Shrinkage Based on Change in Tumor Volume — 2; 33 participants
Phase 3 N=1,501 Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
Stage IB Lung Non-Small Cell Carcinoma AJCC v7 · Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 · Stage IIB Lung Non-Small Cell Carcinoma AJCC v7
Primary: Overall Survival — NA; 85.8 months — p=0.90